Holly RUMERY, Research  Development  - InnOvOtionByHolly  - Owner founder

Holly RUMERY

Research Development

InnOvOtionByHolly

Owner founder

LINCOLN, NE | United States

Main Specialties: Allergy & Immunology, Biochemical Genetics, Biology, Biotechnology, Blood Banking - Transfusion Medicine, Child Neurology, Clinical & Laboratory Immunology, Emergency Medicine, Infectious Disease, Medical Genetics, Oncology, Preventive Medicine, Public Health

Additional Specialties: Project management

ORCID logohttps://orcid.org/0000-0002-2688-8592


Top Author

Holly RUMERY, Research  Development  - InnOvOtionByHolly  - Owner founder

Holly RUMERY

Research Development

Metrics

Number of Publications

101

Publications

Number of Profile Views

547

Profile Views

Number of Article Reads

1606

Reads

Number of PubMed Central Citations

4300

PubMed Central Citations

Education

Sep 2018
Berkley University
Extraterrestrial study
Sep 2005
Tyler junior college
ROTC

Experience

Dec 2011
NASA Ames Research Center
Host /Project Leader / humanitarians activist
Dec 2011
University of California Berkeley
Extraterestrial studys BioMedical agricuture engieering
InnOvOtion by Holly
Bioengineering

Top co-authors

Dara L Aisner
Dara L Aisner

University of Colorado Cancer Center

26
Robert C Doebele
Robert C Doebele

University of Colorado

25
Wilbur A Franklin
Wilbur A Franklin

University of Colorado

14
Fred R Hirsch
Fred R Hirsch

University of Colorado Cancer Center

14
Anh T Le
Anh T Le

School of Economics and Finance

12
Paul A Bunn
Paul A Bunn

University of Colorado Cancer Center

9
Antonio Jimeno
Antonio Jimeno

University of Colorado Cancer Center

9
Wells A Messersmith
Wells A Messersmith

University of Colorado Cancer Center

8
Xian Lu
Xian Lu

University of Colorado Denver

7

Publications

101Publications

1606Reads

4300PubMed Central Citations

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples.

J Thorac Oncol 2018 Oct 20;13(10):1474-1482. Epub 2018 Jun 20.

Department of Medicine - Division of Medical Oncology, University of Colorado - Anschutz Medical Campus, Aurora, Colorado. Electronic address:

View Article
October 2018
17 Reads
5.28 Impact Factor

Citizenship

Authors:
Holly Rumery

InnOvOtionByHolly

https://drive.google.com/file/d/1kDoiJ7quHhe3G5TctLtwMKHL4fqYcDhU/view?usp=drivesdk

View Article
September 2018
9 Reads

Resistance Mechanisms to Targeted Therapies in and Non-small Cell Lung Cancer.

Clin Cancer Res 2018 Jul 10;24(14):3334-3347. Epub 2018 Apr 10.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.

View Article
July 2018
11 Reads
1 PubMed Central Citation(source)
8.72 Impact Factor

EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study.

J Thorac Oncol 2018 Feb 20;13(2):228-236. Epub 2017 Nov 20.

Division of Medical Oncology, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado. Electronic address:

View Article
February 2018
12 Reads
1 PubMed Central Citation(source)
5.28 Impact Factor

Assessment of biologically aggressive, recurrent glandular odontogenic cysts for mastermind-like 2 (MAML2) rearrangements: histopathologic and fluorescent in situ hybridization (FISH) findings in 11 cases.

J Oral Pathol Med 2018 Feb 27;47(2):192-197. Epub 2017 Nov 27.

Division of Medical Oncology and University of Colorado Cancer Center, Anschutz Medical Campus, University of Colorado, Aurora, CO, USA.

View Article
February 2018
7 Reads
1.87 Impact Factor

Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries.

Am Soc Clin Oncol Educ Book 2017 ;37:403-408

From the University of Colorado School of Medicine, University of Colorado Cancer Center, International Association for the Study of Lung Cancer, Aurora, CO; Institute for Pulmonary Diseases of Vojvodina, University of Novi Sad, Sremska Kamenica, Serbia; National Cancer Institute, Cairo University, Giza, Egypt; Chiang Mai University, Chiang Mai, Thailand; Pathology Department, Chiang Mai University, Chiang Mai, Thailand; Hospital Italiano Buenos Aires, Perón, Argentina; University of Colorado Anschutz Medical Campus, Aurora, CO.

View Article
December 2017
12 Reads

MET-GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors.

Clin Cancer Res 2017 Nov 29;23(22):7084-7096. Epub 2017 Aug 29.

Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, Florida.

View Article
November 2017
11 Reads
1 PubMed Central Citation(source)
8.72 Impact Factor

Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.

J Thorac Oncol 2017 10 19;12(10):1512-1523. Epub 2017 Jun 19.

Department of Medicine, Division of Medical Oncology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado; Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

View Article
October 2017
17 Reads
1 PubMed Central Citation(source)
5.28 Impact Factor

Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.

J Mol Diagn 2017 09 9;19(5):682-696. Epub 2017 Aug 9.

Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio; Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, Ohio. Electronic address:

View Article
September 2017
18 Reads
1 PubMed Central Citation(source)
4.85 Impact Factor

A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas.

Oncotarget 2017 Aug 10;8(31):50489-50499. Epub 2016 Jun 10.

Hamon Center for Therapeutic Oncology Research, Department of Pathology and Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.

View Article
August 2017
23 Reads
2 PubMed Central Citations(source)
6.36 Impact Factor

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.

Mol Cancer Ther 2017 08 12;16(8):1623-1633. Epub 2017 May 12.

Division of Medical Oncology, or

View Article
August 2017
22 Reads
3 PubMed Central Citations(source)
5.68 Impact Factor

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 07 6;12(7):e85-e88. Epub 2017 Mar 6.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. Electronic address:

View Article
July 2017
3 Reads
1 PubMed Central Citation(source)
5.28 Impact Factor

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

Cancer Res 2017 07 20;77(13):3551-3563. Epub 2017 Apr 20.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.

View Article
July 2017
371 Reads
13 PubMed Central Citations(source)
9.33 Impact Factor

MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.

PLoS One 2016 26;11(10):e0165107. Epub 2016 Oct 26.

Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA, 30322, United States of America.

View Article
June 2017
11 Reads
3 PubMed Central Citations(source)
3.23 Impact Factor

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.

J Thorac Oncol 2017 01 21;12(1):141-144. Epub 2016 Sep 21.

Clinical Oncology, Cancer Institute of the State of São Paulo, School of Medicine, University of São Paulo, São Paulo, Brazil; Sírio Libanês Hospital, São Paulo, Brazil.

View Article
January 2017
8 Reads
4 PubMed Central Citations(source)
5.28 Impact Factor

An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.

J Thorac Oncol 2016 12 6;11(12):2248-2252. Epub 2016 Sep 6.

University Health Network, Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article
December 2016
15 Reads
1 PubMed Central Citation(source)
5.28 Impact Factor

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.

J Thorac Oncol 2016 08 9;11(8):1273-1281. Epub 2016 Apr 9.

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, University of Colorado, Aurora, Colorado. Electronic address:

View Article
August 2016
56 Reads
13 PubMed Central Citations(source)
5.28 Impact Factor

Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.

J Thorac Oncol 2016 08 1;11(8):1293-1304. Epub 2016 Jun 1.

University of Colorado School of Medicine, Division of Medical Oncology, Aurora, Colorado. Electronic address:

View Article
August 2016
9 Reads
14 PubMed Central Citations(source)
5.28 Impact Factor

Molecular Profiling of a Rare Rosette-Forming Glioneuronal Tumor Arising in the Spinal Cord.

PLoS One 2015 15;10(9):e0137690. Epub 2015 Sep 15.

Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil; Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal; 3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.

View Article
May 2016
10 Reads
3 PubMed Central Citations(source)
3.23 Impact Factor

Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

J Cancer 2016 20;7(6):633-49. Epub 2016 Mar 20.

3. Department of Medicine, University of Colorado, Anschutz Medical Campus, 12801 East 17th Ave, RC1 South, L18-8118, Mail Stop 8117, Aurora, Colorado, USA 80045.

View Article
April 2016
5 Reads
4 PubMed Central Citations(source)
2.64 Impact Factor

De novo generation of adipocytes from circulating progenitor cells in mouse and human adipose tissue.

FASEB J 2016 Mar 18;30(3):1096-108. Epub 2015 Nov 18.

*Division of Geriatric Medicine, Division of Medical Oncology, and Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, School of Medicine, Flow Cytometry Shared Resource, Molecular Pathology/Cytogenetics Shared Resource, University of Colorado Cancer Center, Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, and Colorado Obesity Research Initiative, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA; Molecular Diagnostic Laboratory, Children's Hospital Colorado, Aurora, Colorado, USA; and Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, and **Center for Stem Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA

View Article
March 2016
21 Reads
17 PubMed Central Citations(source)
5.04 Impact Factor

HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.

J Thorac Oncol 2016 Mar 24;11(3):414-9. Epub 2015 Dec 24.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.

View Article
March 2016
17 Reads
15 PubMed Central Citations(source)
5.28 Impact Factor

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.

J Thorac Oncol 2015 Dec;10(12):e115-8

Division of Medical Oncology, University of Colorado, Aurora, Colorado.

View Article
December 2015
1 Read
1 PubMed Central Citation(source)
5.28 Impact Factor

KIAA1549: BRAF Gene Fusion and FGFR1 Hotspot Mutations Are Prognostic Factors in Pilocytic Astrocytomas.

J Neuropathol Exp Neurol 2015 Jul;74(7):743-54

From the Molecular Oncology Research Center (APB, ACC, AP, RMR), and Department of Pathology (CSN), Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Cancer Center (JS, DLA), and School of Medicine (EM, MVG), University of Colorado, Aurora, Colorado; Department of Neurosurgery(CC), Barretos Cancer Hospital, Barretos, São Paulo, Brazil; Department of Surgery (RSO), and Department of Pathology and Forensic Medicine (APB, LN), Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP), São Paulo, Brazil; Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho (RMR), Braga, Portugal; and ICVS/3B's - PT Government Associate Laboratory(RMR), Braga/Guimarães, Portugal.

View Article
July 2015
6 Reads
12 PubMed Central Citations(source)
3.80 Impact Factor

Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.

J Thorac Oncol 2015 Jul;10(7):1083-90

*Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Institute, Shanghai, People's Republic of China; †Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; ‡Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland; §Institute of Pathology, University Hospital Cologne, Medical Centre, Cologne, Germany; ‖Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado; ¶Department of Craniofacial Biology, University of Colorado Anschutz Medical Campus, Aurora, Colorado; and #Department of Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Institute, Shanghai, People's Republic of China.

View Article
July 2015
16 Reads
7 PubMed Central Citations(source)
5.28 Impact Factor

Macrothrombocytopenia as diagnosis predictor of 22q11 deletion syndrome among patients with congenital heart defects.

Am J Med Genet A 2015 Jun 21;167(6):1406-8. Epub 2015 Apr 21.

Graduate Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil.

View Article
June 2015
6 Reads
1 PubMed Central Citation(source)
2.16 Impact Factor

MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.

Am J Clin Oncol 2015 Apr;38(2):152-8

*Department of Medical Oncology, S. Maria della Misericordia Hospital Departments of †Electronic and Information Engineering ‡Thoracic Surgery §Institute of Pathological Anatomy and Histology, University of Perugia, Perugia, Italy ∥Department of Medicine/Medical Oncology, University of Colorado Cancer Center, Aurora, CO.

View Article
April 2015
5 Reads
4 PubMed Central Citations(source)
2.61 Impact Factor

Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract.

Ther Adv Med Oncol 2015 Mar;7(2):56-62

Department of Hematology and Medical Oncology, Emory University School of Medicine, 1365 Clifton Road, NE, Room C3080, Atlanta, GA 30322, USA.

View Article
March 2015
10 Reads
1 PubMed Central Citation(source)

Congenital heart disease in Southern Brazil: potential impact and prevention.

Int J Cardiol 2015 Jan 1;179:9-10. Epub 2014 Nov 1.

Graduate Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), RS, Brazil; Clinical Genetics, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA) and Complexo Hospitalar Santa Casa de Porto Alegre (CHSCPA), RS, Brazil. Electronic address:

View Article
January 2015
5 Reads
4.04 Impact Factor

Role of hypocalcemia in identification of 22q11 deletion syndrome among patients with congenital heart defects.

Int J Cardiol 2014 Nov 5;177(1):6-7. Epub 2014 Oct 5.

Clinical Genetics, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA) and Complexo Hospitalar Santa Casa de Porto Alegre (CHSCPA), RS, Brazil; Graduate Program in Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), RS, Brazil; Clinical Genetics, Hospital Materno Infantil Presidente Vargas (HMIPV), RS, Brazil. Electronic address:

View Article
November 2014
13 Reads
4.04 Impact Factor

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Nov 27;371(21):1963-71. Epub 2014 Sep 27.

From the Massachusetts General Hospital Cancer Center (A.T.S., L.P.L., Z.Z., J.W.C., A.J.I.), Dana-Farber Cancer Institute (G.I.S.), and Beth Israel Deaconess Medical Center (D.B.C.) - all in Boston; University of California at Irvine, Irvine (S.-H.I.O.), and Pfizer Oncology, La Jolla (W.T., S.M.S., L.M.T., J.G.C., K.D.W.) - both in California; Seoul National University Hospital, Seoul, South Korea (Y.-J.B.); University of Colorado, Aurora (D.R.C., M.V.-G., R.C.D.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); University of Chicago, Chicago (R.S.); Memorial Sloan Kettering Cancer Center, New York (G.J.R.); Karolinska Institutet, Stockholm (Z.Z.); and Rho, Chapel Hill, NC (P.S.).

View Article
November 2014
23 Reads
277 PubMed Central Citations(source)
55.87 Impact Factor

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.

PLoS One 2013 13;8(12):e82236. Epub 2013 Dec 13.

Department of Medicine, Division of Medical Oncology, University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States of America.

View Article
October 2014
8 Reads
30 PubMed Central Citations(source)
3.23 Impact Factor

Screening for 22q11 deletion syndrome among patients with congenital heart defects.

Sao Paulo Med J 2014 ;132(2):125-6

Complexo Hospitalar Santa Casa de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.

View Article
October 2014
3 Reads
0.70 Impact Factor

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.

Urology 2014 Jul 10;84(1):127-31. Epub 2014 May 10.

Department of Pathology, University of Colorado Denver School of Medicine, Aurora, CO.

View Article
July 2014
11 Reads
4 PubMed Central Citations(source)
2.19 Impact Factor

Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer.

J Thorac Oncol 2014 Mar;9(3):e21-3

*Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Institute, People's Republic of China; †Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado; and ‡Department of Pathology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado.

View Article
March 2014
4 Reads
13 PubMed Central Citations(source)
5.28 Impact Factor

Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.

Clin Cancer Res 2014 Mar 3;20(6):1656-65. Epub 2014 Feb 3.

Authors' Affiliations: Department of Medicine, Division of Medical Oncology; Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado; and Onconova Therapeutics Inc, Newtown, Pennsylvania.

View Article
March 2014
10 Reads
12 PubMed Central Citations(source)
8.72 Impact Factor

Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions.

Cancer Prev Res (Phila) 2014 Feb 17;7(2):255-65. Epub 2013 Dec 17.

University of Colorado, Anschutz Medical Campus, 12700, East 19th Avenue, RC2 9th Floor, Aurora, CO 80045.

View Article
February 2014
8 Reads
8 PubMed Central Citations(source)

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

Mol Cancer Res 2014 Jan 2;12(1):111-8. Epub 2013 Dec 2.

University of Colorado School of Medicine Anschutz Medical Campus, 12801 East 17th Avenue, L18-8118, Mail Stop 8117, Aurora, CO 80045.

View Article
January 2014
18 Reads
39 PubMed Central Citations(source)
4.38 Impact Factor

Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.

Cancer 2013 Nov 10;119(22):3968-75. Epub 2013 Sep 10.

Department of Medicine, Division of Medical Oncology, University of Colorado, Denver, Colorado.

View Article
November 2013
4 Reads
10 PubMed Central Citations(source)
4.89 Impact Factor

Genetic stability of bone marrow-derived human mesenchymal stromal cells in the Quantum System.

Cytotherapy 2013 Nov 28;15(11):1323-39. Epub 2013 Aug 28.

Terumo BCT, Inc, Lakewood, Colorado, USA. Electronic address:

View Article
November 2013
1 Read
10 PubMed Central Citations(source)
3.29 Impact Factor

The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.

Mol Cancer Ther 2013 Oct 19;12(10):1994-2005. Epub 2013 Jul 19.

Corresponding Author: Antonio Jimeno, University of Colorado School of Medicine, MS8117, 12801 East 17th Avenue, Room L18-8101B, Aurora, CO 80045.

View Article
October 2013
15 Reads
8 PubMed Central Citations(source)
5.68 Impact Factor

Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.

Cancer 2013 Apr 20;119(8):1467-77. Epub 2012 Dec 20.

Division of Medical Oncology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado, USA.

View Article
April 2013
3 Reads
20 PubMed Central Citations(source)
4.89 Impact Factor

[22q11.2 deletion syndrome and complex congenital heart defects].

Rev Assoc Med Bras (1992) 2011 Jan-Feb;57(1):62-5

Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, RS.

View Article
March 2013
3 Reads
2 PubMed Central Citations(source)
0.92 Impact Factor

Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.

Clin Cancer Res 2013 Jan 7;19(1):291-303. Epub 2012 Nov 7.

Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora, CO 80045, USA.

View Article
January 2013
5 Reads
17 PubMed Central Citations(source)
8.72 Impact Factor

Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.

Clin Cancer Res 2013 Jan 21;19(1):148-57. Epub 2012 Nov 21.

Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

View Article
January 2013
8 Reads
10 PubMed Central Citations(source)
8.72 Impact Factor

Malformations detected by abdominal ultrasound in children with congenital heart disease.

Arq Bras Cardiol 2012 Dec 30;99(6):1092-9. Epub 2012 Nov 30.

Programa de Pós-graduação em Patologia, Fundação Universidade Federal de Ciências da Saúde de Porto Alegre, RS, Brasil.

View Article
December 2012
2 Reads
1 PubMed Central Citation(source)
1.12 Impact Factor

Oncogenic fusions involving exon 19 of ALK.

J Thorac Oncol 2012 Dec;7(12):e44

Department of Medicine, Division of Medical Oncology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado. Electronic address:

View Article
December 2012
1 Read
5.28 Impact Factor

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.

Clin Cancer Res 2012 Sep 23;18(17):4570-9. Epub 2012 Aug 23.

Division of Medical Oncology, University of Colorado, MS 8117, 12801 E. 17th Ave, Aurora, CO 80045, USA.

View Article
September 2012
3 Reads
88 PubMed Central Citations(source)
8.72 Impact Factor

Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.

Cancer 2012 Sep 26;118(18):4502-11. Epub 2012 Jan 26.

Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

View Article
September 2012
15 Reads
66 PubMed Central Citations(source)
4.89 Impact Factor

Biologic and genetics aspects of chagas disease at endemic areas.

J Trop Med 2012 8;2012:357948. Epub 2012 Mar 8.

Department of Especial Education, UNESP São Paulo State University, 17525-900 Campus Marília, SP, Brazil.

View Article
August 2012
10 Reads
3 PubMed Central Citations(source)

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.

J Clin Oncol 2012 Jun 16;30(18):2248-55. Epub 2012 Apr 16.

University of Colorado Cancer Center, 12801 E 17th Ave, Mail Stop 8117, Aurora, CO 80045, USA.

View Article
June 2012
8 Reads
61 PubMed Central Citations(source)
18.43 Impact Factor

ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.

Mol Oncol 2012 Jun 28;6(3):370-81. Epub 2012 Mar 28.

Division of Medical Oncology, University of Colorado Denver and University of Colorado Cancer Center, Aurora, CO 80045, USA.

View Article
June 2012
7 Reads
18 PubMed Central Citations(source)
5.33 Impact Factor

Prognostic patterns in the histopathology of pulmonary adenocarcinoma.

J Clin Oncol 2012 May 5;30(13):1401-3. Epub 2012 Mar 5.

View Article
May 2012
5 Reads
1 PubMed Central Citation(source)
18.43 Impact Factor

Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.

Clin Cancer Res 2012 May;18(9):2704-14

Division of Medical Oncology, University of Colorado Denver and University of Colorado Cancer Center, Denver, Colorado 80045, USA.

View Article
May 2012
11 Reads
17 PubMed Central Citations(source)
8.72 Impact Factor

p95HER2 truncated form in resected non-small cell lung cancer.

J Thorac Oncol 2012 Mar;7(3):520-7

Department of Oncology, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy.

View Article
March 2012
3 Reads
4 PubMed Central Citations(source)
5.28 Impact Factor

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Clin Cancer Res 2012 Mar 10;18(5):1472-82. Epub 2012 Jan 10.

Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80209, USA.

View Article
March 2012
15 Reads
278 PubMed Central Citations(source)
8.72 Impact Factor

HIV-1 Tat increases oxidant burden in the lungs of transgenic mice.

Free Radic Biol Med 2011 Nov 5;51(9):1697-707. Epub 2011 Aug 5.

Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

View Article
November 2011
1 Read
10 PubMed Central Citations(source)
5.74 Impact Factor

Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma.

Urology 2011 Oct 2;78(4):863-7. Epub 2011 Aug 2.

Department of Medicine, University of Colorado, School of Medicine, Aurora, CO, USA.

View Article
October 2011
3 Reads
21 PubMed Central Citations(source)
2.19 Impact Factor

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.

J Thorac Oncol 2011 Apr;6(4):774-80

Department of Medical Oncology, University of Colorado Denver, 1665 North Ursula Street, Room 2256, P.O. Box 6510, Mail Stop F-706, Aurora, CO 80045-0508, USA.

View Article
April 2011
8 Reads
67 PubMed Central Citations(source)
5.28 Impact Factor

Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis.

Clin Cancer Res 2011 Apr 21;17(8):2434-43. Epub 2011 Jan 21.

Departmentsof Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article
April 2011
10 Reads
32 PubMed Central Citations(source)
8.72 Impact Factor

Finding ALK-positive lung cancer: what are we really looking for?

J Thorac Oncol 2011 Mar;6(3):411-3

View Article
March 2011
1 Read
7 PubMed Central Citations(source)
5.28 Impact Factor

Suppression of leukemia development caused by PTEN loss.

Proc Natl Acad Sci U S A 2011 Jan 6;108(4):1409-14. Epub 2011 Jan 6.

Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA.

View Article
January 2011
9 Reads
22 PubMed Central Citations(source)
9.81 Impact Factor

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

Clin Cancer Res 2010 Nov 9;16(22):5581-90. Epub 2010 Nov 9.

Division of Medical Oncology and Department of Pathology, University of Colorado-Denver, 1665 North Ursula Street, Aurora, CO 80045-0508, USA.

View Article
November 2010
3 Reads
83 PubMed Central Citations(source)
8.72 Impact Factor

[Oculo-auriculo-vertebral spectrum in patients with congenital heart defects].

Arq Bras Cardiol 2010 Oct 3;95(4):436-9. Epub 2010 Sep 3.

Universidade Federal de Ciências da Saúde de Porto Alegre.

View Article
October 2010
3 Reads
1 PubMed Central Citation(source)
1.12 Impact Factor

Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer.

Clin Cancer Res 2010 Aug 3;16(16):4165-77. Epub 2010 Aug 3.

Division of Medical Oncology, University of Colorado, Denver, Colorado, USA.

View Article
August 2010
4 Reads
13 PubMed Central Citations(source)
8.72 Impact Factor

De novo generation of white adipocytes from the myeloid lineage via mesenchymal intermediates is age, adipose depot, and gender specific.

Proc Natl Acad Sci U S A 2010 Aug 2;107(33):14781-6. Epub 2010 Aug 2.

Charles C Gates Regenerative Medicine and Stem Cell Biology Program, Department of Pediatrics, Cardiovascular Pulmonary Research Laboratory, University of Colorado, Aurora, CO 80045, USA.

View Article
August 2010
10 Reads
53 PubMed Central Citations(source)
9.81 Impact Factor

Biomarkers are here to stay for clinical research and standard care.

J Thorac Oncol 2010 Aug;5(8):1113-5

View Article
August 2010
1 Read
2 PubMed Central Citations(source)
5.28 Impact Factor

Top co-authors

Dara L Aisner
Dara L Aisner

University of Colorado Cancer Center

26
Robert C Doebele
Robert C Doebele

University of Colorado

25
Wilbur A Franklin
Wilbur A Franklin

University of Colorado

14
Fred R Hirsch
Fred R Hirsch

University of Colorado Cancer Center

14
Anh T Le
Anh T Le

School of Economics and Finance

12
Paul A Bunn
Paul A Bunn

University of Colorado Cancer Center

9
Antonio Jimeno
Antonio Jimeno

University of Colorado Cancer Center

9
Wells A Messersmith
Wells A Messersmith

University of Colorado Cancer Center

8
Xian Lu
Xian Lu

University of Colorado Denver

7